Accelerate Diagnostics Inc (AXDX) : Albion Financial Group Ut scooped up 7,500 additional shares in Accelerate Diagnostics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 70,593 shares of Accelerate Diagnostics Inc which is valued at $952,300.Accelerate Diagnostics Inc makes up approximately 0.16% of Albion Financial Group Ut’s portfolio.
Accelerate Diagnostics Inc opened for trading at $12.81 and hit $13.05 on the upside on Wednesday, eventually ending the session at $12.98, with a gain of 1.01% or 0.13 points. The heightened volatility saw the trading volume jump to 1,29,940 shares. Company has a market cap of $665 M.
Other Hedge Funds, Including , Palo Capital added AXDX to its portfolio by purchasing 13,398 company shares during the most recent quarter which is valued at $180,739. Accelerate Diagnostics Inc makes up approx 0.14% of Palo Capital’s portfolio. Simplex Trading added AXDX to its portfolio by purchasing 4,090 company shares during the most recent quarter which is valued at $53,456. Accelerate Diagnostics Inc makes up approx 0.01% of Simplex Trading’s portfolio. Creative Planning added AXDX to its portfolio by purchasing 1,850 company shares during the most recent quarter which is valued at $24,809.
Many Wall Street Analysts have commented on Accelerate Diagnostics Inc. JP Morgan Initiated Accelerate Diagnostics Inc on Mar 24, 2016 to “Overweight”, Price Target of the shares are set at $17.
Accelerate Diagnostics Inc. is an in-vitro diagnostics company providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The Company is focused on reducing the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours rather than the two to three days required to deliver identification and susceptibility results. It has developed a diagnostic platform the Accelerate ID/AST System (the ID/AST System) intended for the rapid diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST) which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. Accelerate Diagnostics UK Limited is a subsidiary of the Company.